While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...

researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.

Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years. "This agreement presents an opportunity for Moderna to support and ...

Erica Denhoff / Icon Sportswire via Getty Images Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech ...

including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound. Let's discuss the pros and cons of buying Moderna stock.